Article Information
History
- April 21, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Nirosen Vijiaratnam, FRCP1,
- Michael Lawton, PhD2,3,
- Raquel Real, PhD1,10,
- Amanda J Heslegrave, PhD4,5,
- Tong Guo, PhD4,5,
- Dilan Athauda, PhD1,
- Sonia Gandhi, PhD1,
- Christine Girges, PhD1,
- Yoav Ben-Shlomo, PhD3,
- Henrik Zetterberg, MD, PhD4,5,6,7,8,
- Donald G Grosset, MD9,
- Huw R Morris, PhD1,10,
- Thomas Foltynie, PhD1,*,
- PRoBaND clinical consortium
- 1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
- 2School of Social and Community Medicine, University of Bristol, Bristol, UK
- 3Department of Social Medicine, University of Bristol, Bristol, UK
- 4Dementia Research Institute, University College London, London, UK
- 5Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
- 6Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- 7Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- 8Hong Kong Center, for Neurodegenerative Diseases, Hong Kong, People’s Republic of China
- 9Department of Neurology, Southern General Hospital, University of Glasgow and Institute of Neurological Sciences, Glasgow, UK
- 10Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815
- ↵*Corresponding author: Prof Thomas Foltynie, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. Email: t.foltynie{at}ucl.ac.uk
Posted April 21, 2022.
